SANUWAVE Health, Inc. — Q1 2024 Form 10-Q
Business context and reporting period. SANUWAVE develops and commercializes noninvasive medical systems, including UltraMIST and PACE. This unaudited report covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless stated. Amounts below are in U.S. dollars.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $5.786 million | $3.775 million |
| Gross profit and margin | $4.202 million; 73% | $2.513 million; 67% |
| Operating loss | $1.050 million | $1.978 million |
| Net loss | $4.528 million | $13.080 million |
| Adjusted EBITDA (non-GAAP) | Loss of $59,000 | Loss of $1.750 million |
| Cash from operating activities | $1.100 million | Cash used of $371,000 |
| Cash and cash equivalents | $2.936 million at March 31 | $1.797 million at December 31, 2023 |
| Total assets / total liabilities | $23.324 million / $70.919 million | $22.416 million / $65.594 million at December 31, 2023 |
- Revenue rose 53%, driven primarily by UltraMIST, higher consumables-and-parts average selling prices, and increased unit sales. Cost of revenue increased 26%.
- General and administrative expense rose 33% to $3.675 million, mainly from severance and a non-recurring legal settlement. Selling and marketing expense declined 13%.
- Operating cash flow benefited from the $2.5 million one-time payment under a patent license and option agreement; it should not be read as evidence of recurring operating cash generation. Investing cash use was $114,000 and financing cash provided was $42,000.
- Interest expense was $3.560 million. The company recorded a $2.501 million derivative fair-value loss, versus $6.797 million in Q1 2023, and $2.5 million of other income from the license agreement.
Liquidity, debt, and material changes
- Current assets were $10.831 million against current liabilities of $70.184 million. Stockholders’ deficit was $47.595 million, and accumulated deficit was $224.577 million.
- Senior secured debt had a $18.910 million carrying value and was in default at quarter-end; the company also reported $6.118 million of accrued interest, including related-party accrued interest. The default arose from minimum-liquidity provisions; default interest included an incremental 5%.
- Convertible promissory notes had a combined carrying value of $10.004 million. The $4.584 million asset-backed notes converted into convertible notes in January 2024. The company issued warrants with those notes; warrant liability increased to $19.818 million from $14.447 million at year-end.
- Management states that recurring operating losses, defaults on notes, and reliance on future financing raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months from filing. Additional capital is required; financing may be unavailable or materially dilutive. Failure to obtain it could require curtailing or discontinuing operations.
Outlook, transactions, and risks
- No quantitative operating guidance is provided. Management expects to pursue commercialization of UltraMIST and PACE and obtain additional capital in 2024, primarily through the proposed merger with SEP Acquisition Corp. These plans are uncertain.
- The merger agreement requires, among other conditions, at least $12 million of cash and cash equivalents at closing, specified note and warrant holder conversion approvals, regulatory and stockholder approvals, and Nasdaq listing approval. The outside date was extended to May 31, 2024; the filing does not establish that the transaction subsequently closed.
- In March, SANUWAVE licensed intravascular shockwave-related patents exclusively and granted the licensee an option to acquire them for an additional single-digit-million-dollar payment. If the option is not exercised within the specified period, the license terminates and rights revert. The $2.5 million initial payment was recorded as other income.
- The company reported three existing material weaknesses in financial reporting controls, including gaps in expertise for complex accounting and deficiencies in accounting and IT controls. Management’s remediation work includes outside consulting and planned control improvements during 2024; the weaknesses were not yet remediated.
- Risks include the unresolved Celularity dispute concerning the UltraMIST asset license, dependence on a small number of suppliers, potential dilution from financing, and execution and funding conditions for the merger. The company reported no material changes to the risk factors in its 2023 Form 10-K.
Important facts for investors to verify
- Whether the merger closed, met its $12 million cash condition, and delivered sufficient usable funding—and the resulting ownership and dilution.
- Current status of senior-debt defaults, forbearance and creditor remedies, and the company’s near-term cash runway and financing alternatives.
- Whether revenue growth and gross-margin improvement persist, excluding the one-time patent payment when assessing recurring performance and cash flow.
- Progress in remediating material weaknesses and whether subsequent filings disclose any additional control issues or restatements.
- Developments in the Celularity dispute, the patent-option exercise, and any other material contingencies.